| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 5% | $1,604,125 | 1,445,158 | Armistice Capital, LLC | 31 Dec 2024 |
As of 30 Sep 2025, 18 institutional investors reported holding 1,156,930 shares of Iterum Therapeutics plc - Ordinary Shares, $0.01 par value per share (ITRM). This represents 4% of the company’s total 28,961,082 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 643,032 | $215,134 | +$126,037 | $0.32 | 2 |
| 2025 Q3 | 1,156,930 | $773,145 | -$1,029,183 | $0.67 | 18 |
| 2025 Q2 | 2,279,287 | $2,267,892 | +$1,239,830 | $1.00 | 18 |
| 2025 Q1 | 1,026,920 | $1,263,113 | -$169,683 | $1.23 | 16 |
| 2024 Q4 | 1,170,433 | $2,067,781 | -$600,384 | $1.77 | 19 |
| 2024 Q3 | 2,040,704 | $2,224,369 | +$1,747,784 | $1.09 | 15 |
| 2024 Q2 | 431,516 | $494,661 | -$755,281 | $1.14 | 14 |
| 2024 Q1 | 928,604 | $1,430,148 | +$822,710 | $1.54 | 15 |
| 2023 Q4 | 386,502 | $761,362 | +$151,318 | $1.97 | 14 |
| 2023 Q3 | 129,626 | $106,196 | -$164,867 | $0.81 | 10 |
| 2023 Q2 | 367,380 | $393,317 | +$195,367 | $1.07 | 13 |
| 2023 Q1 | 186,639 | $187,168 | -$86,697 | $1.00 | 15 |
| 2022 Q4 | 289,053 | $243,384 | +$35,116 | $0.84 | 16 |
| 2022 Q3 | 206,058 | $332,409 | +$332,413 | $1.61 | 12 |